Abstract
Efalizumab is a recombinant humanized monoclonal antibody designed to selectively and reversibly block the activation, reactivation and trafficking of T-cells that lead to the development of psoriasis. It has been approved in the US in 2003 and in Europe in 2004 for the treatment of adults with moderate to severe chronic plaque psoriasis for whom other systemic treatments or phototherapy have been inadequate or inappropriate. The currently suggested dose of 1mg/kg/wk has been shown to have significant therapeutic effect on psoriasis in several controlled trials. Efalizumab has a favorable safety and tolerability profile and provides dermatologists with a effective and safe treatment alternative. The solution to the conflict which is between the currently high cost of this drug and its suggested continuous use for long-term psoriasis control will dictate the future of efalizumab.
Keywords: Efalizumab, psoriasis, treatment, biologics
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Efalizumab
Volume: 6 Issue: 3
Author(s): Ekin Savk
Affiliation:
Keywords: Efalizumab, psoriasis, treatment, biologics
Abstract: Efalizumab is a recombinant humanized monoclonal antibody designed to selectively and reversibly block the activation, reactivation and trafficking of T-cells that lead to the development of psoriasis. It has been approved in the US in 2003 and in Europe in 2004 for the treatment of adults with moderate to severe chronic plaque psoriasis for whom other systemic treatments or phototherapy have been inadequate or inappropriate. The currently suggested dose of 1mg/kg/wk has been shown to have significant therapeutic effect on psoriasis in several controlled trials. Efalizumab has a favorable safety and tolerability profile and provides dermatologists with a effective and safe treatment alternative. The solution to the conflict which is between the currently high cost of this drug and its suggested continuous use for long-term psoriasis control will dictate the future of efalizumab.
Export Options
About this article
Cite this article as:
Ekin Savk , Efalizumab, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2007; 6 (3) . https://dx.doi.org/10.2174/187152307781368292
DOI https://dx.doi.org/10.2174/187152307781368292 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Effects of Medications Used for the Management of Dyslipidemia on Postprandial Lipemia
Current Medicinal Chemistry Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer’s Disease
Current Alzheimer Research Stem Cell Based Tissue Engineering and Regenerative Medicine: A Review Focusing on Adult Stem Cells
Current Tissue Engineering (Discontinued) Biogenic Peptides and Their Potential Use
Current Pharmaceutical Design Role of Molecular Analysis After Autopsy Negative Sudden Death in the Young
Current Pediatric Reviews Fullerenes for Cancer Diagnosis and Therapy: Preparation, Biological and Clinical Perspectives
Current Drug Metabolism The Multiple Electrocardiographic Manifestations of Ventricular Repolarization Memory
Current Cardiology Reviews Nanofibers Based Tissue Engineering and Drug Delivery Approaches for Myocardial Regeneration
Current Pharmaceutical Design Cardioprotection Against Ischemia/Reperfusion Injury and Chromogranin ADerived Peptides
Current Medicinal Chemistry Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets Nutrigenomic Analysis of Diet-Gene Interactions on Functional Supplements for Weight Management
Current Genomics Cardiovascular Risk in Postmenopausal Women with Polycystic Ovary Syndrome
Current Vascular Pharmacology Investigation on Risk Factor of Vascular Thrombotic Diseases in Patients with Obstructive Sleep Apnea Hypopnea Syndrome
Vascular Disease Prevention (Discontinued) Antihistamines: Past Answers and Present Questions
Current Drug Safety The Effects of Antihypertensive Therapy on Haemostatic Parameters
Current Pharmaceutical Design High-Density Lipoprotein: Key Molecule in Cholesterol Efflux and the Prevention of Atherosclerosis
Current Pharmaceutical Design Phenolic Compounds: the Role of Redox Regulation in Neurodegenerative Disease and Cancer
Mini-Reviews in Medicinal Chemistry Roles of Arterial Baroreceptor Reflex During Bezold-Jarisch Reflex
Current Cardiology Reviews Cigarette Smoking and Angiogenesis: What is the Role of Endothelial Progenitor Cells?
Current Angiogenesis (Discontinued) Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters